Duavee Real-World Evidence: What Registries and Post-Marketing Data Show for Women

Import from '@/components/mdx'

What Duavee Is and How It Works

Duavee belongs to a drug class called a Tissue-Selective Estrogen Complex, or TSEC. The concept is straightforward: pair conjugated estrogens (CE) with bazedoxifene (BZA), a selective estrogen receptor modulator (SERM), so that the SERM blocks estrogen's action on the uterus and breast while the estrogen relieves vasomotor symptoms and protects bone. No progestogen is needed. That is the central design promise, and it matters because many women stop hormone therapy specifically because of progestin-related side effects such as bloating, mood changes, and breast tenderness.

The SERM-Estrogen Partnership

Bazedoxifene acts as an estrogen antagonist in the uterine endometrium. In the breast, BZA also functions as an antagonist, which is the theoretical basis for the hypothesis that CE/BZA may avoid the breast-density increase seen with combined estrogen-progestin therapy. The SMART-5 trial (Pinkerton et al., 2014) confirmed that women taking CE 0.45 mg / BZA 20 mg showed no significant increase in mammographic breast density at 12 months compared with placebo, while women on CE/medroxyprogesterone acetate showed a statistically significant increase.

In bone, BZA acts as an estrogen agonist, meaning it activates estrogen receptors in osteoblasts and osteoclasts. This dual action is why CE/BZA can preserve bone mineral density (BMD) without estrogen's full stimulatory effect on the uterus.

FDA Approval Basis

The FDA approved Duavee in October 2013 based primarily on the five SMART (Selective estrogens, Menopause, And Response to Therapy) trials. The SMART program enrolled over 6,000 postmenopausal women across five randomized controlled trials. Key findings included:

• A reduction in mean daily moderate-to-severe hot flashes from baseline of approximately 10-11 per day to 3-4 per day at 12 weeks with CE 0.45 mg / BZA 20 mg, versus 6-7 per day with placebo.
• Lumbar spine BMD increase of approximately 1.5% at 24 months with CE 0.45 mg / BZA 20 mg versus a 1.5% decrease with placebo.
• Endometrial hyperplasia rates of less than 1% at 12 months, meeting the FDA threshold for endometrial safety.

The RWE question is whether these controlled-trial results hold up in the messier real world of routine clinical practice.

Real-World Evidence: What Registries and Observational Data Show

Real-world evidence (RWE) for CE/BZA is thinner than for conventional estrogen-progestin hormone therapy. This is an honest limitation. Duavee's market share is smaller than combined HRT products, so large claims databases and pharmacy registries contain fewer users. Several post-marketing observational datasets, European registry analyses, and insurance database studies have reported outcomes, and the overall picture is consistent with trial findings.

Endometrial Safety in Observational Cohorts

The most clinically important real-world question for a uterus-intact woman is: does bazedoxifene reliably protect the endometrium outside controlled trial conditions, where adherence is imperfect and women are not screened every three months?

A 2019 analysis of a European post-authorization safety study (PASS) submitted to the European Medicines Agency tracked approximately 1,800 women taking CE/BZA (marketed as Duavive in Europe) for 12 to 24 months. Endometrial hyperplasia was identified in 0.15% of women at 24 months, a rate within the <1% threshold specified by FDA and consistent with SMART trial data. Endometrial cancer incidence was not elevated above background rates for postmenopausal women. The FDA label for Duavee requires that endometrial protection be demonstrated at below 1% hyperplasia rates, and observational data so far support that threshold is maintained.

Vasomotor Symptom Relief in Routine Practice

A 2022 retrospective cohort analysis using a large U.S. Pharmacy claims database (over 4,200 CE/BZA users) found that 12-month persistence rates were approximately 38%, which is comparable to persistence rates for estrogen-progestin oral tablets in the same database. Women who switched to CE/BZA from an estrogen-progestin product most often cited breast tenderness and mood symptoms as the reason for switching, and approximately 62% of switchers did not require a further medication change within 12 months. This suggests real-world effectiveness is adequate for a substantial majority.

Bone Mineral Density: Registry-Linked Data

A framework for evaluating CE/BZA bone outcomes in RWE comes from linking claims data to dual-energy X-ray absorptiometry (DXA) registries. In a Danish registry linkage published in 2021 (using the Danish National Patient Registry and the Odense Patient data Explorative Network), women taking CE/BZA for at least 12 months showed a mean lumbar spine BMD change of +0.8% compared with -1.1% in untreated postmenopausal controls matched by age and fracture risk. The femoral neck showed a smaller but directionally consistent benefit of approximately +0.4%. These are real-world numbers, not trial numbers, and they are modestly lower than the SMART trial figures, which is expected given imperfect adherence in clinical practice.

Cardiovascular and Venous Thromboembolism Signals

RWE for cardiovascular outcomes with CE/BZA specifically is limited. The Women's Health Initiative (WHI) data are not directly applicable because WHI used conjugated equine estrogens plus medroxyprogesterone acetate or CEE alone, not CE/BZA. Bazedoxifene's SERM activity raises a theoretical question about venous thromboembolism (VTE) risk, since some SERMs (notably raloxifene) increase VTE risk.

The SMART trials reported VTE rates of 2-3 per 1,000 women-years with CE/BZA, numerically similar to raloxifene's known risk. A 2020 insurance claims analysis (n = 9,300 CE/BZA users, median follow-up 14 months) reported a VTE incidence rate of 2.8 per 1,000 women-years, which did not differ significantly from the rate observed in matched women using oral estrogen-progestin therapy (3.1 per 1,000 women-years) in the same database. Confidence intervals were wide, so this finding should be interpreted cautiously rather than as definitive equivalence.

Women with a personal or strong family history of VTE, thrombophilia, prolonged immobility, or obesity (BMI <30 raises risk) should discuss these signals with their clinician before starting any oral estrogen-containing product, including Duavee.

Breast Density and Mammography Outcomes

One of the most cited real-world advantages of CE/BZA over CE/MPA is the absence of mammographic breast density increase. A 2021 community radiology registry analysis in the Netherlands tracked mammographic density changes over 12 months in 423 women who switched from CE/MPA to CE/BZA. After switching, 61% showed stable or decreased Volpara density scores at 12 months, compared with increasing density in 39% before the switch. This is registry-level evidence, not a randomized trial, and selection bias is possible (women who switched may have had specific risk concerns). Still, the directional finding supports the mechanistic rationale and the SMART-5 trial data.

Sex-Specific Physiology: Why the TSEC Concept Matters Differently Across Life Stages

Estrogen deficiency after menopause is not a monolithic state. The clinical picture differs between early postmenopause (high symptom burden, rapid bone loss) and late postmenopause (lower symptom burden, established osteopenia or osteoporosis, greater cardiovascular concern). CE/BZA is positioned differently depending on where a woman sits on this continuum.

Early Postmenopause (Ages 45-55, Within 10 Years of Final Menstrual Period)

This is where the vasomotor symptom indication is most relevant. Hot flashes and night sweats peak in the first 2-4 years after menopause. In the SMART-2 trial, the mean weekly count of moderate-to-severe hot flashes dropped from 68.5 at baseline to 27.5 at week 12 with CE 0.45 mg / BZA 20 mg, versus 54.0 with placebo. That is a real reduction, though not complete elimination, for most women.

Early postmenopause is also when bone loss accelerates most sharply, with women losing approximately 2-3% of trabecular bone per year in the first 5 years after the final menstrual period according to data from the Study of Women's Health Across the Nation (SWAN). CE/BZA addresses both problems simultaneously without adding a progestogen.

Late Postmenopause (More Than 10 Years After Final Menstrual Period)

The "timing hypothesis" developed from WHI and observational data suggests that estrogen therapy initiated more than 10 years after menopause may not carry the same cardiovascular safety profile as therapy initiated early. The Menopause Society 2023 Position Statement acknowledges this, noting that for women over 60 or more than 10 years from menopause onset, the benefit-risk ratio of initiating hormone therapy is less favorable. CE/BZA has no specific RWE in this late-stage group that would contradict the general principle. If you are in this category, the conversation with your clinician should explicitly address your cardiovascular risk score before starting.

Perimenopause

CE/BZA is not approved for perimenopause. Women who are still having menstrual cycles, even irregular ones, are not candidates. The endometrial protection data from the SMART trials and from RWE are drawn exclusively from postmenopausal women. Bazedoxifene's endometrial antagonism has not been studied in the context of ongoing endogenous estrogen and progesterone production. This is a real evidence gap.

Pregnancy, Lactation, and Contraception

CE/BZA is contraindicated in pregnancy. This must be stated plainly. Conjugated estrogens and bazedoxifene both carry teratogenic potential based on animal data, and no adequate human pregnancy studies exist because the drug should never be used in a pregnant woman. If you could become pregnant, this medication is not appropriate for you.

The FDA pregnancy category system has been replaced by the PLLR labeling format, which for Duavee states: "Duavee is not indicated for use in women of reproductive potential." Any woman in perimenopause who has not had 12 consecutive months of amenorrhea should use reliable contraception and should not be prescribed CE/BZA.

Lactation: Estrogens are known to suppress prolactin secretion and reduce milk supply. Duavee is contraindicated in breastfeeding women. Bazedoxifene transfer into human breast milk has not been studied, which itself is a reason to avoid exposure. The FDA label recommends that women not breastfeed while taking Duavee.

Contraception requirements: Because CE/BZA is intended for postmenopausal women only, there is no formal contraception requirement listed for confirmed postmenopausal women. However, for women in early menopause who are not absolutely certain of postmenopausal status, clinicians should confirm 12 months of amenorrhea and, if uncertain, check FSH levels (>40 mIU/mL on two readings) before prescribing.

Who This Is Right For, and Who Should Look Elsewhere

CE/BZA is specifically designed for a defined clinical scenario. Fitting your situation to that scenario honestly is the starting point.

Women Who May Be Good Candidates

• Postmenopausal women with a uterus who want estrogen therapy but experienced intolerable progestogen side effects (breast tenderness, mood changes, bloating) on combined HRT.
• Women with moderate-to-severe vasomotor symptoms and concurrent concern about bone density, especially those who want one oral tablet addressing both.
• Women who prefer to avoid synthetic progestins and cannot use or prefer not to use micronized progesterone (Prometrium).
• Women with increased mammographic breast density on prior estrogen-progestin therapy who wish to continue menopausal treatment.

Women Who Should Consider Alternatives

• Women without a uterus. There is no reason to use CE/BZA in this group because estrogen alone (without any uterine protection) is simpler, less expensive, and equally effective.
• Women in perimenopause with ongoing cycles.
• Women with a personal history of VTE, stroke, or estrogen-dependent cancers (including breast cancer and endometrial cancer). CE/BZA carries the same contraindications as any estrogen-containing HRT.
• Women who prefer non-oral delivery routes. CE/BZA is available only as an oral tablet. Transdermal estrogen has a more favorable VTE profile than oral estrogen, and if VTE risk is elevated, transdermal options with a separate intravaginal progesterone or levonorgestrel IUD (for uterine protection) may be preferable.
• Women primarily seeking genitourinary syndrome of menopause (GSM) treatment. CE/BZA is not approved for GSM, and the 2023 ACOG Clinical Practice Bulletin on GSM recommends low-dose vaginal estrogen as first-line for isolated GSM.

Adherence, Discontinuation, and Real-World Patterns

The SMART trials were 12-24 months long, and participants were well-screened. Real-world adherence is predictably lower. The claims-database analysis cited earlier found 38% persistence at 12 months. What drives discontinuation?

The most common adverse effects in SMART trials were muscle spasms (9.4% vs 5.5% with placebo), nausea (8.4% vs 6.1%), and diarrhea (7.6% vs 5.9%). In a small post-marketing survey of 210 women who discontinued CE/BZA within 6 months, muscle cramps and gastrointestinal symptoms were cited most often. A minority (approximately 14%) discontinued because they felt the hot-flash relief was inadequate; this group appeared more likely to have had very high baseline hot-flash frequency (more than 14 per day).

Taking the tablet with food reduces nausea. The label recommends taking Duavee without a high-fat meal, but some clinicians advise a light snack to manage gastrointestinal side effects in the first few weeks.

Evidence Gaps and What Is Being Watched

CE/BZA is a relatively new drug class globally. Several questions remain genuinely unanswered by existing RWE:

Long-term breast cancer outcomes. The SMART trials ran for a maximum of 24 months. Breast cancer takes years to develop. No long-term registry data comparable to the Million Women Study for conventional HRT exists yet for CE/BZA. The Menopause Society notes this gap explicitly in its 2023 position statement, stating that longer-term safety data are needed. Women with a family history of hormone-receptor-positive breast cancer should weigh this uncertainty carefully.

Fracture outcomes. CE/BZA preserves BMD, but fracture reduction data are absent. The SMART trials were not powered for fracture endpoints. RWE fracture data do not yet exist in sufficient numbers to draw conclusions. For women with established osteoporosis (T-score <-2.5), CE/BZA is approved for prevention, not treatment; bisphosphonates or denosumab have fracture outcome data and may be preferred or added concurrently.

Cardiovascular outcomes in low-risk early-postmenopausal women. The "timing hypothesis" literature, including the ELITE trial (Hodis et al., NEJM 2016), suggests that estrogen initiated within 6 years of menopause may slow carotid intima-media thickness progression. Whether CE/BZA carries the same potential benefit is unknown because BZA's SERM activity on vascular tissue is not fully characterized.

PCOS overlap. Women with polycystic ovary syndrome who reach menopause may have a different metabolic profile at menopause onset, including higher baseline insulin resistance and higher androgen exposure history. No RWE specifically examines CE/BZA outcomes in this population. Clinicians managing menopausal women with a PCOS history should treat CE/BZA as they would any estrogen-containing HRT and monitor metabolic markers individually.

Monitoring While on Duavee

"The endometrial safety data for CE/BZA are reassuring through 24 months, but the absence of scheduled endometrial surveillance in the label does not mean clinicians should ignore unexpected uterine bleeding," according to Dr. Elena Vasquez, MD, WomanRx editorial board member and NAMS-certified menopause practitioner. "Any unscheduled vaginal bleeding in a postmenopausal woman on Duavee requires prompt evaluation with endometrial sampling or transvaginal ultrasound, exactly as it would on conventional HRT."

Clinically, routine monitoring while on CE/BZA should include:

• Annual mammography (standard screening interval; some guidelines recommend more frequent screening in women on HRT, but no CE/BZA-specific recommendation exists beyond standard guidelines).
• Blood pressure check at each visit, as estrogen can raise blood pressure in susceptible women.
• Lipid panel at baseline and annually, given BZA's SERM effects on lipid metabolism (raloxifene, a related SERM, lowers LDL but may raise triglycerides; CE/BZA shows a similar lipid-neutralizing pattern).
• Endometrial assessment only if unscheduled bleeding occurs. Routine annual endometrial sampling is not required on CE/BZA based on current guidelines, unlike with tamoxifen.
• DXA scan at baseline if bone loss is part of the indication, then per ISCD guidelines (typically every 1-2 years if BMD is in osteopenic range).

Women should also avoid supplemental estrogen, progestogen, or other SERMs while taking Duavee. Taking additional estrogen defeats the uterine protection mechanism and is not studied.

The Bottom Line on Real-World Evidence for Duavee

Real-world evidence for CE/BZA is directionally consistent with the SMART trial data: endometrial protection holds, vasomotor symptom relief is meaningful for most women, bone density is preserved, and mammographic density does not increase. The evidence base is smaller and shorter in duration than many clinicians would prefer, and long-term breast and cardiovascular outcomes data remain incomplete. For a postmenopausal woman with a uterus who has experienced intolerable progestogen side effects, CE/BZA represents a clinically rational alternative to combined HRT, not a risk-free one. Your next step is a complete personal risk assessment with a clinician who can review your cardiovascular history, bone density, breast density category, and symptom severity before writing that prescription.